RESUMEN
To evaluate the possible role of central free amino compounds in pediatric opsoclonus-myoclonus syndrome (OMS), 21 cerebrospinal fluid (CSF) amino compounds were measured by an amino acid analyzer or mass spectroscopy in 74 anesthetized children, 54 with OMS and 20 age-matched neurological controls. In OMS, only phosphoethanolamine was increased compared to controls; OMS severity and duration had significant converse effects on alanine and phosphoethanolamine. In contrast, corticotropin (ACTH) treatment was associated with increased alanine and phenylalanine, and decreased taurine compared to controls and untreated OMS, and increased glutamine, lysine, ornithine, and tyrosine compared to untreated OMS. Other than low taurine, these effects were not found with corticosteroid treatment, and non-steroidogenic immunotherapy had no effect. The ACTH dose-association was most apparent for alanine and phosphoethanolamine, but lysine and ornithine were also higher in the high-dose ACTH group. There were no significant disease- or treatment-associated perturbations in GABA, glycine, or other amino acids. These data suggest a unique pattern of ACTH effects on non-neurotransmitter CSF amino compounds, for the most part not shared by steroids.
Asunto(s)
Hormona Adrenocorticotrópica/uso terapéutico , Aminoácidos/líquido cefalorraquídeo , Inmunoterapia/métodos , Síndrome de Opsoclonía-Mioclonía/tratamiento farmacológico , Hormona Adrenocorticotrópica/farmacología , Alanina/líquido cefalorraquídeo , Alanina/metabolismo , Aminoácidos/metabolismo , Análisis de Varianza , Niño , Preescolar , Cromatografía de Gases/métodos , Corticosterona/farmacología , Corticosterona/uso terapéutico , Relación Dosis-Respuesta a Droga , Femenino , Glutamina/líquido cefalorraquídeo , Glutamina/metabolismo , Humanos , Lisina/líquido cefalorraquídeo , Lisina/metabolismo , Masculino , Espectrometría de Masas/métodos , Síndrome de Opsoclonía-Mioclonía/líquido cefalorraquídeo , Síndrome de Opsoclonía-Mioclonía/metabolismo , Ornitina/líquido cefalorraquídeo , Ornitina/metabolismo , Fenilalanina/líquido cefalorraquídeo , Fenilalanina/metabolismo , Índice de Severidad de la Enfermedad , Taurina/líquido cefalorraquídeo , Taurina/metabolismo , Tirosina/líquido cefalorraquídeo , Tirosina/metabolismoRESUMEN
BACKGROUND: For ethnic minority patients where a suitably matched BM or peripheral blood donor is frequently unavailable, cord blood offers an opportunity for hematopoietic stem cell transplantation. Focused recruitment of ethnic minorities for cord blood donation has been proposed as the preferred strategy to improve access for minority recipients to cord blood for transplantation. The aim of this study was to evaluate cord blood characteristics for Caucasian and African American donors and the success of ethnically mismatched UC blood transplantation in African American recipients. METHODS: Retrospective data analysis was performed comparing the characteristics of 556 cord blood units from African American and Caucasian donors. The outcomes of 18 African American ethnically mismatched transplant recipients were compared with a paired sample of 18 ethnically matched Caucasian recipients. RESULTS: The fraction of collected units meeting acceptability criteria from African Americans was significantly lower compared with Caucasians (P = <0.0001). Additionally, African Americans had a significantly lower post-processing total nucleated cell count (TNC) compared with Caucasians (P=0.007) but there were no other significant differences in conventionally measured product characteristics. In the transplant analysis, there was no difference in overall survival at 1 year (P=0.85) or time to neutrophil engraftment (P=0.92) between the two patient populations. DISCUSSION: At comparable levels of TNC dose and HLA matching, the use of ethnically mismatched UC blood units as a source for allogeneic unrelated transplant can result in successful transplant outcomes for African American patients.
Asunto(s)
Negro o Afroamericano , Trasplante de Células Madre de Sangre del Cordón Umbilical/etnología , Trasplante de Células Madre Hematopoyéticas/etnología , Población Blanca , Bancos de Sangre , Donantes de Sangre , Trasplante de Células Madre de Sangre del Cordón Umbilical/mortalidad , Trasplante de Células Madre de Sangre del Cordón Umbilical/estadística & datos numéricos , Sangre Fetal/citología , Enfermedad Injerto contra Huésped/epidemiología , Trasplante de Células Madre Hematopoyéticas/métodos , Trasplante de Células Madre Hematopoyéticas/mortalidad , Trasplante de Células Madre Hematopoyéticas/estadística & datos numéricos , Humanos , Recién Nacido , Leucemia/terapia , Estudios Retrospectivos , Análisis de SupervivenciaRESUMEN
The mucopolysaccharidoses (MPS) is characterized by accumulation of glycosaminoglycans (GAGs), and mucolipidosis (ML) by accumulation of GAGs and sphingolipids. Each type of MPS accumulates specific GAGs. The lysosomal enzymes N-acetylgalactosamine-6-sulphate sulphatase and beta-galactosidase involve the stepwise degradation of keratan sulphate (KS). Deficiency of these enzymes results in elevation of KS levels in the body fluids and in tissues, leading to MPS IV disease. In this study, we evaluated blood and urine KS levels in types of MPS and ML other than MPS IV. Eighty-five plasma samples came from MPS I (n = 18), MPS II (n = 28), MPS III (n = 20), MPS VI (n = 3), MPS VII (n = 5) and ML (n = 11) patients while 127 urine samples came from MPS I (n = 34), MPS II (n = 34), MPS III (n = 32), MPS VI (n = 7), MPS VII (n = 9) and ML (n = 11) patients. KS levels were determined using the ELISA method. Plasma KS levels varied with age in both control and patient populations. In all age groups, the mean values of plasma KS in MPS and ML patients were significantly higher than those in the age-matched controls. Plasma KS values in four newborn patients were above the mean + 2SD of the age-matched controls (mean, 41 ng/ml). Overall, 85.9% of individual values in non-type IV MPS and ML patients were above the mean + 2SD of the age-matched controls. For urine KS levels, 24.4% of individual values in patients were above the mean + 2SD of the age-matched controls. In conclusion, KS in blood is elevated in each type of non-type IV MPS examined, in contrast to the conventional understanding. This finding suggests that measurement of KS level provides a new diagnostic biomarker in a wide variety of mucopolysaccharidoses and mucolipidoses in addition to MPS IV.
Asunto(s)
Sulfato de Queratano/sangre , Sulfato de Queratano/orina , Mucolipidosis/metabolismo , Mucopolisacaridosis/metabolismo , Adolescente , Adulto , Factores de Edad , Anciano , Anciano de 80 o más Años , Especificidad de Anticuerpos , Biomarcadores , Niño , Preescolar , Reacciones Cruzadas , Ensayo de Inmunoadsorción Enzimática , Humanos , Lactante , Recién Nacido , Sulfato de Queratano/inmunología , Persona de Mediana Edad , Mucolipidosis/diagnóstico , Mucopolisacaridosis/diagnóstico , Sensibilidad y EspecificidadRESUMEN
Phospholipase A2 (PLA2) catalyzes the hydrolysis of sn-2 fatty acids from membrane phospholipids resulting in the production of several biologically active phospholipid metabolites such as lysophospholipids, arachidonic acid, eicosanoids and platelet-activating factor. The majority of myocardial PLA2 activity is membrane-associated and does not require Ca2+ for activity (iPLA2). Myocardial iPLA2 demonstrates unique characteristics when compared to other PLA2 isoforms described previously, including a selectivity for plasmalogen phospholipids and resistance to inhibition by methyl arachidonyl fluorophosphonate. Activation of myocardial iPLA2 results in the production of lysoplasmenylcholine and arachidonic acid, both of which can change the electrophysiologic properties of the myocardium. Arachidonic acid can modulate ion channel activity via protein kinase C activation and has been demonstrated to decrease gap junctional conductance. Lysoplasmenylcholine directly produces action potential derangements and alters calcium cycling in cardiac myocytes. Thus, inhibition of iPLA2 activity to block production of phospholipid metabolites that mediate pathologic changes in the myocardium would be of considerable benefit. However, there are situations where inhibition of PLA2 activity would be detrimental to the myocardium, in particular if iPLA2 acts as a phospholipid repair enzyme following oxidative damage. Although little is known regarding the function of cPLA2 or sPLA2 in the myocardium, it is possible that they may be important for signal transduction or may modulate the activity of iPLA2.
Asunto(s)
Miocardio/enzimología , Fosfolipasas A/metabolismo , Animales , Calcio/metabolismo , Enfermedades Cardiovasculares/enzimología , Enfermedades Cardiovasculares/fisiopatología , Catálisis , Fosfolipasas A2 Grupo VI , Humanos , Isoenzimas/química , Isoenzimas/metabolismo , Fosfolipasas A/antagonistas & inhibidores , Fosfolipasas A/química , Fosfolipasas A/clasificación , Fosfolipasas A2 , Transducción de Señal/fisiologíaRESUMEN
In clinical medicine, particularly in the newly developing stem cell therapies required to support the practice of regenerative medicine, the measurement of both CD34+ and CD34- hematopoietic stem cells (HSC)/hematopoietic progenitor cells (HPC) is important in obtaining more accurate information about the total HSC/HPC content in various stem/progenitor cell sources. We report the results of an investigation into methods of detecting CD34+ and CD34- HSC/HPC using the immature information (IMI) channel incorporated into the Sysmex XE-2100 and SE-9000 automated hematology analyzers. In this study, CD34+ and CD34- HSC/HPC were separated by immunologic methods and quantified by flow cytometry (FACScan) and IMI channel analysis. In addition, CD34-/CD133+ HSC were prepared by a sequential antibody-based positive selection strategy. These cells appeared in the same area as CD34+ cells in the IMI channel of the automated hematology analyzer. These findings confirmed that an automated hematology analyzer can be used to measure both CD34+ and CD34- HSC. These results may explain the difference in HSC/HPC counts sometimes observed between the automated hematology analyzer and flow cytometric methods for CD34+ measurement. The results of this study demonstrated the potential of automated cell counting methods for measuring HSC content in cellular products for both research and clinical applications.
Asunto(s)
Antígenos CD34/análisis , Recuento de Células Sanguíneas/instrumentación , Células Madre Hematopoyéticas/citología , Antígeno AC133 , Antígenos CD , Automatización , Forma de la Célula , Citometría de Flujo , Glicoproteínas/análisis , Humanos , Péptidos/análisisRESUMEN
Platelet activating factor (PAF) is a potent lipid autocoid that is rapidly synthesized and presented on the surface of endothelial cells following thrombin stimulation. PAF production may occur via de novo synthesis or by the combined direct action of phospholipase A(2) (PLA(2)) and acetyl-CoA:lyso-PAF acetyltransferase or via the remodeling pathway. This study was undertaken to define the role of PLA(2) and plasmalogen phospholipid hydrolysis in PAF synthesis in thrombin-treated human umbilical artery endothelial cells (HUAEC). Basal PLA(2) activity in HUAEC was primarily found to be Ca(2+)-independent (iPLA(2)), membrane-associated, and selective for arachidonylated plasmenylcholine substrate. Thrombin stimulation of HUAEC resulted in a preferential 3-fold increase in membrane-associated iPLA(2) activity utilizing plasmenylcholine substrates with a minimal increase in activity with alkylacyl glycerophospholipids. No change in cystolic iPLA(2) activity in thrombin-stimulated HUAEC was observed. The thrombin-stimulated activation of iPLA(2) and associated hydrolysis of plasmalogen phospholipids was accompanied by increased levels of arachidonic acid (from 1.1 +/- 0.1 to 2.8 +/- 0.1%) and prostacyclin release (from 38 +/- 12 to 512 +/- 24%) as well as an increased level of production of lysoplasmenylcholine (from 0.6 +/- 0.1 to 2.1 +/- 0.3 nmol/mg of protein), lysophosphatidylcholine (from 0.3 +/- 0.1 to 0.6 +/- 0.1 nmol/mg of protein), and PAF (from 790 +/- 108 to 3380 +/- 306 dpm). Inhibition of iPLA(2) with bromoenol lactone resulted in inhibition of iPLA(2) activity, plasmalogen phospholipid hydrolysis, production of choline lysophospholipids, and PAF synthesis. These data indicate that PAF production requires iPLA(2) activation in thrombin-stimulated HUAEC and may occur through the CoA-independent transacylase remodeling pathway rather than as a direct result of the PLA(2)-catalyzed hydrolysis of membrane alkylacyl glycerophosphocholine.
Asunto(s)
Endotelio Vascular/efectos de los fármacos , Fosfolipasas A/metabolismo , Factor de Activación Plaquetaria/biosíntesis , Trombina/farmacología , Cromatografía Líquida de Alta Presión , Relación Dosis-Respuesta a Droga , Endotelio Vascular/citología , Endotelio Vascular/metabolismo , Fosfolipasas A2 Grupo VI , Humanos , Lípidos de la Membrana/metabolismo , Naftalenos/farmacología , Inhibidores de Fosfodiesterasa/farmacología , Fosfolípidos/metabolismo , Pironas/farmacologíaRESUMEN
The diagnosis of acute infection with human immunodeficiency virus (HIV) presents a challenge for the primary care provider. We present a case of early HIV infection and discuss the limitations of the currently established diagnostic algorithm for HIV infection. We conclude that alternative diagnostic testing for human immunodeficiency virus type 1 (HIV-1) RNA is warranted in certain clinical settings. Appropriate, early diagnosis of HIV infection may improve the patient's outcome and provide additional public health benefits by reducing transmission of disease.
Asunto(s)
Infecciones por VIH/diagnóstico , VIH-1 , Enfermedad Aguda , Adulto , Algoritmos , Western Blotting , Recuento de Linfocito CD4 , Diagnóstico Diferencial , Proteína p24 del Núcleo del VIH/sangre , Humanos , Técnicas para Inmunoenzimas , Masculino , ARN Viral/sangre , Carga ViralRESUMEN
We compared troponin I (TnI) assays (AxSYM [Abbott]; ACS:180 [Bayer]) in blood samples with concentrations less than 10 ng/mL (< 10 micrograms/L). Discordant results were evaluated by linearity studies and by testing for rheumatoid factor. Patients with discordant TnI results were compared with patients with concordant results and patients with negative TnI who had a new myocardial infarction or died within 2 months of initial testing. Positive TnI cutoffs by AxSYM and ACS:180 were 0.7 ng/mL (0.7 microgram/L) and 0.13 ng/mL (0.13 microgram/L), respectively. We identified 173 specimens that were repeatedly positive by at least 1 assay; 143 specimens were positive by both assays. Twenty samples positive for TnI by AxSYM were negative by ACS:180, while 10 samples positive by ACS:180 were negative by AxSYM. The discordant samples showed no evidence of interfering substances, including rheumatoid factor. Clinical follow-up showed that 26% of patients with elevated TnI by both assays, 33% with TnI positive only by AxSYM, 22% with TnI positive only by ACS:180, and 8% with negative TnI by AxSYM encountered at least 1 clinical end point. Variable detection rates by these assays for low-positive TnI represent a clinically significant problem.
Asunto(s)
Inmunoensayo/métodos , Indicadores y Reactivos , Troponina I/sangre , Anciano , Biomarcadores/sangre , Femenino , Insuficiencia Cardíaca/sangre , Hospitales de Veteranos , Humanos , Masculino , Infarto del Miocardio/sangre , Valores de Referencia , Reproducibilidad de los ResultadosRESUMEN
PURPOSE: Protease activated receptors (PAR) represent a family of G protein coupled receptors with 7 membrane spanning domains that are activated by proteolysis of the N-terminus of the receptor by serine proteases. The presence of multiple PARs on the same cell is thought to extend the range of proteases a cell responds to rather than expand the range of intracellular responses. We investigated arachidonic acid and prostaglandin E2 release in the human urothelial carcinoma cell line RT4 in response to stimulation with thrombin, which activates PAR-1, and tryptase, which activates PAR-2. MATERIALS AND METHODS: RT4 cells were incubated with thrombin, tryptase or PAR agonist peptides and intracellular phospholipase A2 (PLA2) activity, arachidonic acid and prostaglandin E2 release were measured. Pretreatment with bromoenol lactone, a selective inhibitor for Ca2+ independent PLA2 (iPLA2), was also investigated. RESULTS: Thrombin and tryptase stimulation resulted in a 2 to 3-fold increase in membrane associated iPLA2 that was accompanied by comparative increases in arachidonic acid and prostaglandin E2 release. These responses were also observed when synthetic peptides representing the tethered ligand for each receptor were incubated with RT4 cells. Arachidonic acid and prostaglandin E2 release, and iPLA2 activation were completely inhibited by pretreatment with bromoenol lactone. CONCLUSIONS: Stimulating RT4 cells with PAR-1 or PAR-2 leads to the selective activation of iPLA2 as well as the release of arachidonic acid and prostaglandin E2, which may provide cytoprotection during an acute inflammatory reaction.
Asunto(s)
Ácido Araquidónico/metabolismo , Proteínas de Caenorhabditis elegans , Carcinoma de Células Transicionales/metabolismo , Proteínas de Unión al GTP/metabolismo , Fosfolipasas A/metabolismo , Serina Endopeptidasas/fisiología , Neoplasias de la Vejiga Urinaria/metabolismo , Membrana Celular/fisiología , Dinoprostona/metabolismo , Proteínas del Helminto/metabolismo , Humanos , Fosfolipasas A2 , Proteínas Serina-Treonina Quinasas/metabolismo , Serina Endopeptidasas/farmacología , Trombina/farmacología , Triptasas , Células Tumorales Cultivadas , Urotelio/metabolismoAsunto(s)
Enfermedades Cardiovasculares/enzimología , Enfermedades Cardiovasculares/fisiopatología , Fosfolipasas A/fisiología , Animales , Progresión de la Enfermedad , Activación Enzimática/efectos de los fármacos , Humanos , Isoenzimas/metabolismo , Isoenzimas/fisiología , Isquemia Miocárdica/enzimología , Miocardio/enzimología , Fosfolipasas A/metabolismo , Fosfolipasas A2 , Plasmalógenos/metabolismo , Remodelación Ventricular/fisiologíaRESUMEN
Diabetes-induced changes in phospholipase A(2) (PLA(2)) activity have been measured in several tissues but are undefined in diabetic myocardium. We measured ventricular PLA(2) activity in control, streptozotocin-induced diabetic, and insulin-treated diabetic rats and characterized myocardial phospholipids to determine whether diabetes altered myocardial phospholipid metabolism. Increased membrane-associated Ca(2+)-independent PLA(2) (iPLA(2)) activity was observed in diabetes that was selective for arachidonylated phospholipids. Increased iPLA(2) activity was accompanied by an increase in choline lysophospholipids. Diabetes was associated with marked alterations in the phospholipid composition of the myocardium, characterized by decreases in esterified arachidonic and docosahexaenoic acids and increases in linoleic acid. The decrease in polyunsaturated fatty acids was confined to diacylphospholipids, whereas the relative amount of these fatty acids in plasmalogens was increased. Diabetes-induced changes in PLA(2) activity, lysophospholipid production, and alterations in phospholipid composition were all reversed by insulin treatment of diabetic animals. Diabetes-induced changes in membrane phospholipid content and phospholipid hydrolysis may contribute to some of the alterations in myocardial function that are observed in diabetic patients.
Asunto(s)
Calcio/fisiología , Diabetes Mellitus Experimental/metabolismo , Ácidos Grasos Insaturados/metabolismo , Miocardio/metabolismo , Fosfolipasas A/metabolismo , Plasmalógenos/metabolismo , Animales , Glucemia/análisis , Peso Corporal , Diabetes Mellitus Experimental/enzimología , Diabetes Mellitus Experimental/patología , Inducción Enzimática , Immunoblotting , Isoenzimas/metabolismo , Cetonas/sangre , Masculino , Miocardio/enzimología , Fosfolípidos/metabolismo , Ratas , Ratas Sprague-Dawley , Valores de ReferenciaRESUMEN
Thrombin stimulation of rabbit ventricular myocytes activates a membrane-associated, Ca(2+)-independent phospholipase A(2) (PLA(2)) capable of hydrolyzing plasmenylcholine (choline plasmalogen), plasmanylcholine (alkylacyl choline phospholipid), and phosphatidylcholine substrates. To identify the endogenous phospholipid substrates, we quantified the effects of thrombin stimulation on diradyl phospholipid mass and arachidonic acid and lysophospholipid production. Thrombin stimulation resulted in a selective decrease in arachidonylated plasmenylcholine, with no change in arachidonylated phosphatidylcholine. The decrease in arachidonylated plasmenylcholine was accompanied by an increase in plasmenylcholine species containing linoleic and linolenic acids at the sn-2 position. A decrease in arachidonylated plasmenylethanolamine was also observed after thrombin stimulation, with no concomitant change in arachidonylated phosphatidylethanolamine. Thrombin stimulation resulted in the selective production of lysoplasmenylcholine, with no increase in lysophosphatidylcholine content. There was no evidence for significant acetylation of lysophospholipids to form platelet-activating factor. Arachidonic acid released after thrombin stimulation was rapidly oxidized to prostacyclin. Thus thrombin-stimulated Ca(2+)-independent PLA(2) selectively hydrolyzes arachidonylated plasmalogen substrates, resulting in production of lysoplasmalogens and prostacyclin as the principal bioactive products.
Asunto(s)
Miocardio/metabolismo , Fosfolipasas A/metabolismo , Plasmalógenos/metabolismo , Trombina/farmacología , Animales , Ácido Araquidónico/metabolismo , Calcio/fisiología , Epoprostenol/biosíntesis , Femenino , Ácido Linoleico/análisis , Lisofosfatidilcolinas/metabolismo , Masculino , Miocardio/citología , Oxidación-Reducción , Plasmalógenos/química , Conejos , Especificidad por Sustrato , Ácido alfa-Linolénico/análisisRESUMEN
We studied the feasibility of routine diagnostic testing for HIV-1 RNA at a publicly funded testing site. HIV-1 RNA was determined with a commercial polymerase chain reaction assay in pooled seronegative blood samples submitted for HIV testing to a public health laboratory. Recovery of HIV-1 RNA from the samples was estimated as at least 8% of viral RNA that was found in freshly prepared plasma. We estimated that screening for HIV-1 RNA in serum pools would result in the identification of blood specimens from more than 95% of acutely infected patients. The frequency of HIV-1 RNA in seronegative blood samples was estimated to be between 19 and 601 per 10(6) submitted specimens. The ratio of HIV-1 RNA positive and seronegative samples to specimens with HIV-1 antibodies confirmed by Western blot was estimated to be between 0.2% and 6.6%. The reagent costs for identifying 1 HIV-infected blood sample were 10-fold higher with the commercially available HIV-1 RNA assay compared with the HIV antibody enzyme-linked immunosorbent assay. Diagnostic testing for HIV-1 RNA may be warranted in high-risk populations since acutely infected patients may benefit most from anti-retroviral therapy and are thought to contribute disproportionately to the HIV epidemic.
Asunto(s)
Infecciones por VIH/diagnóstico , Seronegatividad para VIH , VIH-1/genética , ARN Viral/sangre , Western Blotting , Ensayo de Inmunoadsorción Enzimática , Estudios de Factibilidad , Anticuerpos Anti-VIH/análisis , Infecciones por VIH/sangre , VIH-1/inmunología , Humanos , Reacción en Cadena de la PolimerasaRESUMEN
The present study was performed to characterize thrombin-stimulated phospholipase A2 (PLA2) activity and the resultant release of lysophospholipids from endothelial cells. The majority of PLA2 activity in endothelial cells was membrane associated, Ca2+ independent, and arachidonate selective. Incubation with thrombin increased membrane-associated PLA2 activity using both plasmenylcholine and alkylacyl glycerophosphocholine substrates in the absence of Ca2+, with no increase in activity observed with phosphatidylcholine substrate. The increased PLA2 activity was accompanied by arachidonic acid and lysoplasmenylcholine (LPlasC) release from endothelial cells into the surrounding medium. Thrombin-induced changes were duplicated by stimulation with the thrombin-receptor-directed peptide SFLLRNPNDKYEPF. Pretreatment with the Ca2+-independent PLA2 inhibitor bromoenol lactone blocked thrombin-stimulated increases in PLA2 activity, arachidonic acid, and LPlasC release. Stimulation of protein kinase C (PKC) increased basal PLA2 activity and LPlasC production. Thrombin-stimulated PLA2 activity and LPlasC production were enhanced with PKC activation and completely prevented with PKC downregulation. Thus thrombin treatment of endothelial cells activates a PKC-activated, membrane-associated, Ca2+-independent PLA2 that selectively hydrolyzes arachidonylated, ether-linked phospholipid substrates, resulting in LPlasC and arachidonic acid release.
Asunto(s)
Endotelio Vascular/metabolismo , Plasmalógenos/metabolismo , Trombina/farmacología , Animales , Ácido Araquidónico/metabolismo , Células Cultivadas , Endotelio Vascular/citología , Activación Enzimática/fisiología , Hidrólisis/efectos de los fármacos , Lisofosfolípidos/metabolismo , Naftalenos/farmacología , Fragmentos de Péptidos/farmacología , Inhibidores de Fosfodiesterasa/farmacología , Fosfolipasas A/metabolismo , Fosfolipasas A2 , Proteína Quinasa C/metabolismo , Pironas/farmacología , Porcinos , Trombina/antagonistas & inhibidoresRESUMEN
Accelerated phospholipid catabolism occurs early after the onset of myocardial ischemia and is likely to be mediated by the activation of one or more phospholipases in ischemic tissue. We hypothesized that hypoxia increases phospholipase A2 (PLA2) activity in isolated ventricular myocytes, resulting in increased lysophospholipid and arachidonic acid production, contributing to arrhythmogenesis in ischemic heart disease. The majority of ventricular myocyte arachidonic acid was found in plasmalogen phospholipids. Hypoxia increased membrane-associated, Ca2+-independent, plasmalogen-selective PLA2 activity, resulting in increased arachidonic acid release and lysoplasmenylcholine production. Pretreatment with the specific Ca2+-independent PLA2 inhibitor bromoenol lactone blocked hypoxia-induced increases in PLA2 activity, arachidonic acid release, and lysoplasmenylcholine production. Lysoplasmenylcholine produced action potential derangements, including shortening of action potential duration, and induced early and delayed afterdepolarizations in normoxic myocytes. The electrophysiological alterations induced by lysoplasmenylcholine would likely contribute to the initiation of arrhythmogenesis in the ischemic heart.
Asunto(s)
Hipoxia de la Célula , Miocardio/enzimología , Fosfolipasas A/metabolismo , Fosfolípidos/metabolismo , Plasmalógenos/metabolismo , Potenciales de Acción/efectos de los fármacos , Adenosina Trifosfato/metabolismo , Adenosina Trifosfato/farmacología , Animales , Ácido Araquidónico/metabolismo , Calcio/farmacología , Membrana Celular/enzimología , Femenino , Ventrículos Cardíacos/enzimología , Hidrólisis , Cinética , Lisofosfolípidos/metabolismo , Lisofosfolípidos/farmacología , Miocardio/ultraestructura , Naftalenos/farmacología , Inhibidores de Fosfodiesterasa/farmacología , Fosfolipasas A2 , Fosfolípidos/análisis , Pironas/farmacología , ConejosRESUMEN
Activation of phospholipase A2 (PLA2) and accumulation of lysophosphatidylcholine contribute importantly to arrhythmogenesis during acute myocardial ischemia. We examined thrombin stimulation of PLA2 activity in isolated ventricular myocytes. Basal and thrombin-stimulated cardiac myocyte PLA2 activity demonstrated a distinct preference for sn-1 ether-linked phospholipids with arachidonate esterified at the sn-2 position. The majority of PLA2 activity was calcium independent and membrane associated. Thrombin stimulation of membrane-associated PLA2 occurs in a time- and concentration-dependent fashion. An increase in PLA2 activity was also observed using the synthetic peptide SFLLRNPNDKYEPF (the tethered ligand generated by thrombin cleavage of its receptor). Bromoenol lactone, a selective inhibitor of calcium-independent PLA2, completely blocked thrombin-stimulated increases in PLA2 activity and arachidonic acid release. No significant inhibition of thrombin-induced PLA2 was observed following pretreatment with mepacrine or dibucaine. These data confirm the presence of high-affinity thrombin receptors on isolated cardiac myocytes and demonstrate the specific activation of a unique membrane-associated, calcium-independent PLA2 following thrombin receptor ligation.
Asunto(s)
Calcio/metabolismo , Miocardio/enzimología , Fosfolipasas A/metabolismo , Trombina/farmacología , Animales , Ácido Araquidónico/metabolismo , Membrana Celular/efectos de los fármacos , Membrana Celular/enzimología , Dibucaína/farmacología , Activación Enzimática , Inhibidores Enzimáticos/farmacología , Femenino , Ventrículos Cardíacos/efectos de los fármacos , Técnicas In Vitro , Naftalenos/farmacología , Fragmentos de Péptidos/metabolismo , Fosfolipasas A/antagonistas & inhibidores , Fosfolipasas A2 , Pironas/farmacología , Quinacrina/farmacología , Conejos , Receptores de Trombina/metabolismoRESUMEN
We characterized phospholipase A2 (PLA2) activity in isolated rabbit ventricular myocytes with respect to subcellular distribution, substrate specificity, and Ca2+ dependency. Membrane-associated PLA2 was found to be an order of magnitude greater than cytosolic PLA2. Ventricular myocyte PLA2 activity was enhanced following protease-activated receptor stimulation with thrombin and was found to be largely Ca2+-independent and selective for phospholipid substrates containing arachidonic acid at the sn-2 position. Immunoblot analysis using an antibody to cytosolic Ca2+-independent PLA2 from Chinese hamster ovary cells recognized a membrane-associated protein with a molecular mass of approximately 80 kDa; however, differences in pH optima, response to inhibitors, and substrate selectivity of membrane-associated and cytosolic PLA2 activity suggest the presence of multiple Ca2+-independent PLA2. Pretreatment with bromoenol lactone, a specific inhibitor of Ca2+-independent PLA2, significantly attenuated membrane-associated and cytosolic PLA2 in unstimulated and thrombin-stimulated myocytes. Pretreatment with methyl arachidonyl fluorophosphonate, mepacrine, or dibucaine had no significant effect on PLA2 activity under all conditions tested. Ventricular myocyte PLA2 activity was significantly inhibited by ATP, GTP, and their nonhydrolyzable analogs and was regulated by protein kinase C activity. These studies demonstrate the presence of one or more unique membrane-associated Ca2+-independent PLA2 in isolated ventricular myocytes that exhibit a preference for phospholipids with arachidonate at the sn-2 position and that are activated by thrombin stimulation.